Maculopathy due to antimalarials, chloroquine (CQ) and hydroxychloroquine (HCQ), is an infrequent but irreversible side effect of chronic treatment with these drugs. It is more common with chloroquine, high daily doses, prolonged treatment duration, concomitant use with tamoxifen, and in the presence of kidney disease or previous maculopathy.
The goal of new screening guidelines is to recognize signs of toxicity very early before it affects visual acuity and becomes visible in the fundus.